MNKD Quote, Financials, Valuation and Earnings

Amicus Therapeutics, Inc. has a net margin of 9.72% compared to MannKind Corp.'s net margin of 10.24%. MannKind Corp.'s return on equity of -- beat Amicus Therapeutics, Inc.'s return on equity of -7.02%.

MannKind Corp. has a consensus price target of $9.61, signalling upside risk potential of 69.81%. On the other hand Amicus Therapeutics, Inc. has an analysts' consensus of $14.50 which suggests that it could grow by 1.33%. Given that MannKind Corp. has higher upside potential than Amicus Therapeutics, Inc., analysts believe MannKind Corp. is more attractive than Amicus Therapeutics, Inc..

MannKind Corp. has a beta of 0.839, which suggesting that the stock is 16.131% less volatile than S&P 500. In comparison Amicus Therapeutics, Inc. has a beta of 0.381, suggesting its less volatile than the S&P 500 by 61.857%.

MannKind Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MannKind Corp. pays -- of its earnings as a dividend. Amicus Therapeutics, Inc. pays out -- of its earnings as a dividend.

MannKind Corp. quarterly revenues are $82.1M, which are smaller than Amicus Therapeutics, Inc. quarterly revenues of $169.1M. MannKind Corp.'s net income of $8M is lower than Amicus Therapeutics, Inc.'s net income of $17.3M. Notably, MannKind Corp.'s price-to-earnings ratio is 60.08x while Amicus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MannKind Corp. is 5.57x versus 7.32x for Amicus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Ionis Pharmaceuticals, Inc. has a net margin of 9.72% compared to MannKind Corp.'s net margin of -82.06%. MannKind Corp.'s return on equity of -- beat Ionis Pharmaceuticals, Inc.'s return on equity of -43.01%.

MannKind Corp. has a consensus price target of $9.61, signalling upside risk potential of 69.81%. On the other hand Ionis Pharmaceuticals, Inc. has an analysts' consensus of $91.13 which suggests that it could grow by 13.06%. Given that MannKind Corp. has higher upside potential than Ionis Pharmaceuticals, Inc., analysts believe MannKind Corp. is more attractive than Ionis Pharmaceuticals, Inc..

MannKind Corp. has a beta of 0.839, which suggesting that the stock is 16.131% less volatile than S&P 500. In comparison Ionis Pharmaceuticals, Inc. has a beta of 0.291, suggesting its less volatile than the S&P 500 by 70.94%.

MannKind Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ionis Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MannKind Corp. pays -- of its earnings as a dividend. Ionis Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

MannKind Corp. quarterly revenues are $82.1M, which are smaller than Ionis Pharmaceuticals, Inc. quarterly revenues of $156.7M. MannKind Corp.'s net income of $8M is higher than Ionis Pharmaceuticals, Inc.'s net income of -$128.6M. Notably, MannKind Corp.'s price-to-earnings ratio is 60.08x while Ionis Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MannKind Corp. is 5.57x versus 13.72x for Ionis Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Keros Therapeutics, Inc. has a net margin of 9.72% compared to MannKind Corp.'s net margin of -51.05%. MannKind Corp.'s return on equity of -- beat Keros Therapeutics, Inc.'s return on equity of 9.94%.

MannKind Corp. has a consensus price target of $9.61, signalling upside risk potential of 69.81%. On the other hand Keros Therapeutics, Inc. has an analysts' consensus of $23.00 which suggests that it could grow by 37.97%. Given that MannKind Corp. has higher upside potential than Keros Therapeutics, Inc., analysts believe MannKind Corp. is more attractive than Keros Therapeutics, Inc..

MannKind Corp. has a beta of 0.839, which suggesting that the stock is 16.131% less volatile than S&P 500. In comparison Keros Therapeutics, Inc. has a beta of 0.857, suggesting its less volatile than the S&P 500 by 14.332%.

MannKind Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Keros Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MannKind Corp. pays -- of its earnings as a dividend. Keros Therapeutics, Inc. pays out -- of its earnings as a dividend.

MannKind Corp. quarterly revenues are $82.1M, which are larger than Keros Therapeutics, Inc. quarterly revenues of $14.3M. MannKind Corp.'s net income of $8M is higher than Keros Therapeutics, Inc.'s net income of -$7.3M. Notably, MannKind Corp.'s price-to-earnings ratio is 60.08x while Keros Therapeutics, Inc.'s PE ratio is 10.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MannKind Corp. is 5.57x versus 2.73x for Keros Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals, Inc. has a net margin of 9.72% compared to MannKind Corp.'s net margin of 36.91%. MannKind Corp.'s return on equity of -- beat Vertex Pharmaceuticals, Inc.'s return on equity of 22.97%.

MannKind Corp. has a consensus price target of $9.61, signalling upside risk potential of 69.81%. On the other hand Vertex Pharmaceuticals, Inc. has an analysts' consensus of $526.50 which suggests that it could grow by 5.21%. Given that MannKind Corp. has higher upside potential than Vertex Pharmaceuticals, Inc., analysts believe MannKind Corp. is more attractive than Vertex Pharmaceuticals, Inc..

MannKind Corp. has a beta of 0.839, which suggesting that the stock is 16.131% less volatile than S&P 500. In comparison Vertex Pharmaceuticals, Inc. has a beta of 0.303, suggesting its less volatile than the S&P 500 by 69.725%.

MannKind Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MannKind Corp. pays -- of its earnings as a dividend. Vertex Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

MannKind Corp. quarterly revenues are $82.1M, which are smaller than Vertex Pharmaceuticals, Inc. quarterly revenues of $3.2B. MannKind Corp.'s net income of $8M is lower than Vertex Pharmaceuticals, Inc.'s net income of $1.2B. Notably, MannKind Corp.'s price-to-earnings ratio is 60.08x while Vertex Pharmaceuticals, Inc.'s PE ratio is 32.05x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MannKind Corp. is 5.57x versus 10.50x for Vertex Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.